Join the Qulipta group to help and get support from people like you.
Qulipta News
Quick Fix? New Migraine Medicine, Qulipta, May Start Working Right Away
THURSDAY, Dec. 26, 2024 – Migraine patients often suffer a long time before docs zero in on the best dosage for drugs designed to prevent their terrible symptoms. But a recently approved daily...
Atogepant Superior for Efficacy, Functional Measures in Migraine
THURSDAY, Dec. 26, 2024 – For adults with migraine, atogepant 60 mg once daily was superior to placebo for efficacy and functional measures of treatment across three trials, according to research...
Atogepant Efficacious for Patients With Chronic Migraine
WEDNESDAY, June 26, 2024 – For patients with chronic migraine (CM), with and without medication overuse, atogepant is efficacious, according to a study published online June 27 in Neurology. Peter...
Migraine Prevention Med Quilipta Might Stop 'Rebound' Headaches, Too
THURSDAY, June 27, 2024 – It's a nasty cycle: Chronic migraine sufferers who use too much pain medication sometimes get smacked with rebound headaches. But new research suggests that a medication...
U.S. FDA Approves Qulipta (atogepant) for Adults With Chronic Migraine
NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of Qulipta (atogepant) ...
FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine
NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of...
Further information
Related condition support groups
Chronic Migraine, Migraine Prevention, Migraine Prophylaxis